Epstein-Barr Virus Early Antigen (EBV EA) (AA 306-390) Peptide
EBV EA
Reactivité: Epstein-Barr Virus (EBV)
Hôte: Escherichia coli (E. coli)
ELISA, WB
N° du produit ABIN2129000
Aperçu rapide pour Epstein-Barr Virus Early Antigen (EBV EA) (AA 306-390) Peptide (ABIN2129000)
Antigène
EBV EA
(Epstein-Barr Virus Early Antigen (EBV EA))
Origine
Epstein-Barr Virus (EBV)
Source
Escherichia coli (E. coli)
Application
ELISA, Western Blotting (WB)
Type de proteíne
Recombinant
Protein Region
AA 306-390
Attributs du produit
Purified recombinant EBV EA protein Expression System: E.coli
Purification
Proprietary chromatographic technique
Pureté
> 95 % pure
Indications d'application
Each Investigator should determine their own optimal working dilution for specific applications.
Restrictions
For Research Use only
Buffer
50 mM tris-HCl, pH 8.0, with 10 mM glutation, 60 mM NaCl and 0.5 % sarcosyl.
Conseil sur la manipulation
Avoid repeated freeze/thaw cycles.
Stock
RT/-20 °C
Antigène
EBV EA
(Epstein-Barr Virus Early Antigen (EBV EA))
Classe de substances
Viral Protein
Sujet
The Epstein-Barr virus (EBV), also called Human herpes virus 4 (HHV-4), is a virusof the herpes family (which includes Herpes simplex virusand Cytomegalo virus. On infecting the B-lymphocyte, the linear virus genome circularizes and the virus subsequently persists within the cell as an episome. The virus can execute several distinct programs of gene expressionwhich can be broadly categorized as being lytic cycle or latent cycle. The lytic cycleor productive infection results in staged expression of a host of viral proteinswith the ultimate objective of producing infectious virions. Formally, this phase of infection does not inevitably lead to lysis of the host cellas EBV virions are produced by budding from the infected cell. The latent cycle(lysogenic) programs are those that do not result in production of virions. Alternative Names: EBV HHV4 EA protein, Epstein Barr, Epstein-Barr Virus Early Antigen protein